FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2993155890> ?p ?o ?g. }

• W2993155890 endingPage "2341" @default.
• W2993155890 startingPage "2331" @default.
• W2993155890 abstract "The aim of this study was to assess if prior oral anticoagulant agent (OAC) use modifies the lower bleeding risk observed with dabigatran dual therapy (dabigatran twice daily plus a P2Y12 inhibitor) versus warfarin triple therapy (warfarin plus a P2Y12 inhibitor plus aspirin) in patients with atrial fibrillation who underwent percutaneous coronary intervention (PCI).In the RE-DUAL PCI (Randomized Evaluation of Dual Antithrombotic Therapy With Dabigatran Versus Triple Therapy With Warfarin in Patients With Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention) trial, the primary outcome of major bleeding or clinically relevant nonmajor bleeding was lower with dabigatran dual therapy versus warfarin triple therapy in patients with atrial fibrillation who underwent PCI.A total of 2,725 patients were randomized to dual therapy with dabigatran (110 or 150 mg twice daily) plus clopidogrel or ticagrelor or triple therapy with warfarin plus aspirin and clopidogrel or ticagrelor. Subgroup analysis compared risk for major bleeding or clinically relevant nonmajor bleeding and a composite thromboembolic endpoint in patients with prior OAC use and in those who were OAC treatment naive.Risk for major bleeding or clinically relevant nonmajor bleeding was reduced with both dabigatran dual therapies compared with warfarin triple therapy in both the prior OAC use group (hazard ratios: 0.58 [95% confidence interval (CI): 0.42 to 0.81] and 0.61 [95% CI: 0.41 to 0.92] with 110 and 150 mg dabigatran, respectively) and the OAC-naive group (hazard ratios: 0.49 [95% CI: 0.38 to 0.63] and 0.76 [95% CI: 0.59 to 0.97] with 110 and 150 mg dabigatran) (p for interaction = 0.42 and 0.37, 110 and 150 mg dabigatran, respectively). The risk for thromboembolic events seemed similar with dabigatran dual therapy (both doses) and warfarin triple therapy across subgroups.Bleeding risk was reduced with dabigatran dual therapy versus warfarin triple therapy in patients with atrial fibrillation after PCI, regardless of whether they were prior OAC users or OAC treatment naive. These results suggest that it is also safe to switch patients on OAC pre-PCI to dabigatran dual therapy post-PCI." @default.
• W2993155890 created "2019-12-13" @default.
• W2993155890 creator A5007123733 @default.
• W2993155890 creator A5009430890 @default.
• W2993155890 creator A5026004870 @default.
• W2993155890 creator A5026602252 @default.
• W2993155890 creator A5028136226 @default.
• W2993155890 creator A5037551685 @default.
• W2993155890 creator A5038405190 @default.
• W2993155890 creator A5041974328 @default.
• W2993155890 creator A5056522927 @default.
• W2993155890 creator A5063859581 @default.
• W2993155890 creator A5074250560 @default.
• W2993155890 creator A5078418468 @default.
• W2993155890 creator A5081852908 @default.
• W2993155890 creator A5091860770 @default.
• W2993155890 date "2019-12-01" @default.
• W2993155890 modified "2023-09-30" @default.
• W2993155890 title "Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation" @default.
• W2993155890 cites W1090493624 @default.
• W2993155890 cites W1573872903 @default.
• W2993155890 cites W1775839320 @default.
• W2993155890 cites W1913182214 @default.
• W2993155890 cites W1972632922 @default.
• W2993155890 cites W1976469399 @default.
• W2993155890 cites W2002588893 @default.
• W2993155890 cites W2004413589 @default.
• W2993155890 cites W2031640679 @default.
• W2993155890 cites W2042608661 @default.
• W2993155890 cites W2078973349 @default.
• W2993155890 cites W2096246254 @default.
• W2993155890 cites W2097854437 @default.
• W2993155890 cites W2099422917 @default.
• W2993155890 cites W2105397247 @default.
• W2993155890 cites W2123251249 @default.
• W2993155890 cites W2135241452 @default.
• W2993155890 cites W2136489990 @default.
• W2993155890 cites W2137878797 @default.
• W2993155890 cites W2144471064 @default.
• W2993155890 cites W2159370853 @default.
• W2993155890 cites W2162508946 @default.
• W2993155890 cites W2163305028 @default.
• W2993155890 cites W2164615468 @default.
• W2993155890 cites W2324403620 @default.
• W2993155890 cites W2406884255 @default.
• W2993155890 cites W2508853990 @default.
• W2993155890 cites W2623061081 @default.
• W2993155890 cites W2724431303 @default.
• W2993155890 cites W2749929702 @default.
• W2993155890 cites W2754054868 @default.
• W2993155890 cites W2765673436 @default.
• W2993155890 cites W2792857103 @default.
• W2993155890 cites W2802512131 @default.
• W2993155890 cites W3004050106 @default.
• W2993155890 cites W3126662497 @default.
• W2993155890 cites W4236531408 @default.
• W2993155890 cites W5418977 @default.
• W2993155890 cites W3026981879 @default.
• W2993155890 doi "https://doi.org/10.1016/j.jcin.2019.08.039" @default.
• W2993155890 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31806214" @default.
• W2993155890 hasPublicationYear "2019" @default.
• W2993155890 type Work @default.
• W2993155890 sameAs 2993155890 @default.
• W2993155890 citedByCount "8" @default.
• W2993155890 countsByYear W29931558902019 @default.
• W2993155890 countsByYear W29931558902020 @default.
• W2993155890 countsByYear W29931558902021 @default.
• W2993155890 countsByYear W29931558902022 @default.
• W2993155890 countsByYear W29931558902023 @default.
• W2993155890 crossrefType "journal-article" @default.
• W2993155890 hasAuthorship W2993155890A5007123733 @default.
• W2993155890 hasAuthorship W2993155890A5009430890 @default.
• W2993155890 hasAuthorship W2993155890A5026004870 @default.
• W2993155890 hasAuthorship W2993155890A5026602252 @default.
• W2993155890 hasAuthorship W2993155890A5028136226 @default.
• W2993155890 hasAuthorship W2993155890A5037551685 @default.
• W2993155890 hasAuthorship W2993155890A5038405190 @default.
• W2993155890 hasAuthorship W2993155890A5041974328 @default.
• W2993155890 hasAuthorship W2993155890A5056522927 @default.
• W2993155890 hasAuthorship W2993155890A5063859581 @default.
• W2993155890 hasAuthorship W2993155890A5074250560 @default.
• W2993155890 hasAuthorship W2993155890A5078418468 @default.
• W2993155890 hasAuthorship W2993155890A5081852908 @default.
• W2993155890 hasAuthorship W2993155890A5091860770 @default.
• W2993155890 hasBestOaLocation W29931558901 @default.
• W2993155890 hasConcept C126322002 @default.
• W2993155890 hasConcept C164705383 @default.
• W2993155890 hasConcept C207103383 @default.
• W2993155890 hasConcept C2776301958 @default.
• W2993155890 hasConcept C2777628954 @default.
• W2993155890 hasConcept C2777849778 @default.
• W2993155890 hasConcept C2778810321 @default.
• W2993155890 hasConcept C2779161974 @default.
• W2993155890 hasConcept C2780400711 @default.
• W2993155890 hasConcept C2780890252 @default.
• W2993155890 hasConcept C44249647 @default.
• W2993155890 hasConcept C45393284 @default.
• W2993155890 hasConcept C500558357 @default.

• next